Ilyang Pharmaceutical Co Ltd (007575) - Total Assets
Based on the latest financial reports, Ilyang Pharmaceutical Co Ltd (007575) holds total assets worth ₩444.81 Billion KRW (≈ $301.44 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Ilyang Pharmaceutical Co Ltd (007575) shareholders funds for net asset value and shareholders' equity analysis.
Ilyang Pharmaceutical Co Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Ilyang Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Ilyang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Ilyang Pharmaceutical Co Ltd's total assets of ₩444.81 Billion consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.0% |
| Accounts Receivable | ₩44.96 Billion | 10.4% |
| Inventory | ₩59.87 Billion | 13.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩25.34 Billion | 5.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Ilyang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ilyang Pharmaceutical Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilyang Pharmaceutical Co Ltd's current assets represent 29.1% of total assets in 2024, a decrease from 36.8% in 2014.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2024, down from 3.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
Ilyang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Ilyang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Ilyang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.87 | 0.88 | 0.97 |
| Quick Ratio | 0.42 | 0.51 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-20.45 Billion | ₩-24.77 Billion | ₩-6.33 Billion |
Ilyang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ilyang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.9% |
| Total Assets | ₩431.21 Billion |
| Market Capitalization | $159.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilyang Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ilyang Pharmaceutical Co Ltd's assets grew by 20.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ilyang Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual total assets of Ilyang Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩431.21 Billion ≈ $292.23 Million |
+20.90% |
| 2023-12-31 | ₩356.66 Billion ≈ $241.70 Million |
-28.41% |
| 2022-12-31 | ₩498.19 Billion ≈ $337.61 Million |
+0.79% |
| 2021-12-31 | ₩494.27 Billion ≈ $334.96 Million |
+12.56% |
| 2020-12-31 | ₩439.12 Billion ≈ $297.58 Million |
+0.38% |
| 2019-12-31 | ₩437.46 Billion ≈ $296.46 Million |
+1.20% |
| 2018-12-31 | ₩432.25 Billion ≈ $292.93 Million |
-0.94% |
| 2017-12-31 | ₩436.37 Billion ≈ $295.72 Million |
+1.19% |
| 2016-12-31 | ₩431.26 Billion ≈ $292.26 Million |
-0.08% |
| 2015-12-31 | ₩431.63 Billion ≈ $292.51 Million |
+0.18% |
| 2014-12-31 | ₩430.83 Billion ≈ $291.97 Million |
-- |
About Ilyang Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more